抗肿瘤药与呼吸系统恶性肿瘤化疗患者骨髓抑制发生风险的Logistic回归分析

Logistic Analysis of Bone Marrow Depression ODDS Risks of Anticancer Drugs in Respiratory System Cancer Patients with Chemotherapy Regiments

目的:研究抗肿瘤药与呼吸系统恶性肿瘤化疗患者骨髓抑制发生风险的关系。方法:收集符合条件的呼吸系统恶性肿瘤化疗患者2 176例,用Logistic回归分析不同种类化疗药物等因素对患者发生骨髓抑制的风险的相关性。结果:年龄、住院天数、费别、植物来源作用于微管蛋白质系统抗肿瘤药、烷化剂、抗代谢抗癌药、抗肿瘤抗菌药、金属络合物的回归系数分别为0.010、0.147、-0.361、-0.642、-0.891、-0.656、0.769、-0.779。结论:年龄和住院天数都对骨髓抑制发生产生正相关作用,参加医保可以降低骨髓抑制的发生风险。对于抗肿瘤药来说,化疗期间发生骨髓抑制危险程度由高到低依次为抗肿瘤抗菌药、抗代谢药物、金属络合物、烷化剂、植物来源作用于微管蛋白质系统抗肿瘤药。

Objective：To study the BMD（bone marrow depression） ODDS relation of antitumor plant alkaloids and other anticancer drugs in respiratory system cancer patients with chemotherapy regiments.Methods：2176 profiles of cancer patients which met the studying condition were investigated.All the profiles were evaluated by deferent variants,and then their variants were analyzed with logistic liner.Results：The line values of ages,days,insurance,plant resource antineoplastic,alkylating agents,antimetabolizor,antitumor antibiotic,platinum antitumor compounds were 0.010,0.147,-0.361,-0.642,-0.891,-0.656,0.769,-0.779.Conclusion：The BMD OR of age and days in hospital increased OR factors but the BMD OR of insurance decreased OR factors.The risk degrees occurring to the BMD OR in the respiratory system cancer patients with chemotherapy regiment were ranked from the higher to lower level as follows： antitumor antibiotic,antimetabolizor,platinum antitumor compounds,alkylating agents,and plant resource antineoplastic.